Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.

Article Details

Citation

Yamazaki H, Shimada T

Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.

Arch Biochem Biophys. 1997 Oct 1;346(1):161-9. doi: 10.1006/abbi.1997.0302.

PubMed ID
9328296 [ View in PubMed
]
Abstract

Roles of human cytochrome P450 (P450 or CYP) 2C9, 2C19, and 3A4 in the oxidation of progesterone and testosterone were studied in recombinant P450 enzymes and in human liver microsomes. In vitro inhibition experiments showed that progesterone and its 17alpha- and 21-hydroxylated metabolites and 11-deoxycortisol suppressed the CYP2C19-dependent R-warfarin 7-hydroxylation activities, with progesterone being the most active. These steroid chemicals also inhibited CYP2C9-dependent S-warfarin 7-hydroxylation activities though lesser extents seen with those in CYP2C19 enzyme. Progesterone was found to be a competitive inhibitor of CYP2C19 and CYP2C9 in human liver microsomes. Recombinant CYP2C19 catalyzed progesterone to form 21-hydroxyprogesterone as a major product and 16alpha- and 17alpha-hydroxyprogesterone as minor products. CYP2C9 also had progesterone 21-hydroxylation activities, although the activities were lower than those catalyzed by CYP2C19. Vmax/Km ratios for the progesterone 21-hydroxylation activity of CYP2C19 were determined to be 13- and 32-fold higher than those of CYP2C9 and 3A4, respectively. CYP3A4 oxidized progesterone to form 16alpha-, 6beta-, and 2beta-hydroxyprogesterone as major products and 21-hydroxyprogesterone as a minor product, but did not produce detectable levels of 17alpha-hydroxyprogesterone. Immunoinhibition experiments suggested that anti-CYP2C9 (which inhibits both CYP2C9 and CYP2C19 catalytic activities) suppressed the progesterone 21-hydroxylation activities catalyzed by liver microsomes of humans and monkeys and that anti-CYP2C11 inhibited the progesterone 21-hydroxylation activities catalyzed by liver microsomes of male rats. CYP2C19 was also found to oxidize testosterone at 17-position to form androstenedione. Androstenedione formation catalyzed by liver microsomes of humans and monkeys and of male rats was suppressed by anti-CYP2C9 and anti-CYP2C11, respectively. These results suggest that CYP2C19 plays important roles in the oxidation of progesterone and testosterone in human liver microsomes, although the physiological significance of these metabolic pathways remains unclear. CYP2C9 may have some, but lesser extent than those by CYP2C19, of the catalytic roles for the metabolism of progesterone and testosterone by human liver microsomes.

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
ProgesteroneCytochrome P450 2C19ProteinHumans
Unknown
Substrate
Inhibitor
Details
ProgesteroneCytochrome P450 2C9ProteinHumans
Unknown
Substrate
Inhibitor
Details
TestosteroneCytochrome P450 2C19ProteinHumans
Unknown
Substrate
Details
Testosterone cypionateCytochrome P450 2C19ProteinHumans
Unknown
Substrate
Details
Testosterone cypionateCytochrome P450 2C9ProteinHumans
Unknown
Substrate
Details
Testosterone enanthateCytochrome P450 2C19ProteinHumans
Unknown
Substrate
Details
Testosterone enanthateCytochrome P450 2C9ProteinHumans
Unknown
Substrate
Details
Testosterone undecanoateCytochrome P450 2C19ProteinHumans
Unknown
Substrate
Details
Testosterone undecanoateCytochrome P450 2C9ProteinHumans
Unknown
Substrate
Details
Drug Reactions
Reaction
Details